Hepatic gluconeogenesis (GNG) (GNG)

Hepatic gluconeogenesis is a vital metabolic pathway responsible for the de novo synthesis of glucose from non-carbohydrate substrates, including lactate, glycerol, and amino acids [StatPearls: Gluconeogenesis]. Primarily occurring in the liver, this process ensures a steady supply of glucose to the brain and red blood cells during prolonged fasting or strenuous exercise [NIH: PMC3510762]. In individuals with Type 2 diabetes, the pathway becomes dysregulated, leading to excessive glucose production and contributing significantly to fasting hyperglycemia [Nature Reviews Endocrinology, 2014]. Therapeutic strategies often focus on inhibiting key regulatory enzymes like Fructose-1,6-bisphosphatase (FBPase) or Phosphoenolpyruvate carboxykinase (PEPCK), or utilizing agents like Metformin that suppress the pathway through AMPK activation and mitochondrial inhibition [PubChem: Metformin]. Additionally, antagonism of the glucagon receptor is a targeted approach to reduce the hormonal drive for gluconeogenesis [PubMed: 25048195]. Managing this pathway is crucial for restoring normoglycemia and reducing the long-term complications associated with chronic metabolic disease.

Other names

Endogenous glucose productionDe novo glucose synthesisLiver gluconeogenesis

Inhibition of rate-limiting enzymes such as Fructose-1,6-bisphosphatase or Phosphoenolpyruvate carboxykinase, and modulation of regulatory signals like AMPK activation or glucagon receptor antagonism to suppress endogenous glucose production [StatPearls: Gluconeogenesis; Nature Reviews Endocrinology, 2014].